Abstract Number: 446 • 2013 ACR/ARHP Annual Meeting
Remission Rates During Golimumab Treatment For Rheumatoid Arthritis Are Associated With Differences In Baseline Disease States Across Geographic Regions
Background/Purpose: Regional differences in practice patterns and access to biologic treatment for rheumatoid arthritis (RA) may lead to regional differences in baseline disease characteristics, which…Abstract Number: 2760 • 2013 ACR/ARHP Annual Meeting
Incidence and Severity Of Myocardial Infarction In Subjects Receiving Anti Tumour Necrosis Factor Drugs For Rheumatoid Arthritis: Results From Linking the British Society For Rheumatology Biologics Register For Rheumatoid Arthritis and Myocardial Ischaemia National Audit Project
Background/Purpose: Subjects with rheumatoid arthritis (RA) are at increased risk of myocardial infarction (MI) compared to subjects without RA, with the increased risk potentially driven…Abstract Number: 2036 • 2013 ACR/ARHP Annual Meeting
Biologic Therapy For Relapsing Polychondritis: Old and New Efficacy Indices
Background/Purpose: The inflammatory milieu in affected tissues from Relapsing Polychondritis (RP) is rich in TNF-α, IL-1-β and IL-6. Cytokine-targeted biologic therapies has therefore been proposed…Abstract Number: 1470 • 2013 ACR/ARHP Annual Meeting
Anti-Tumour Necrosis Factor Alpha Therapy Reduces Platelet Reactivity and Is Associated With Improved Insulin Sensitivity In Patients With Inflammatory Arthritis
Background/Purpose: Patients with inflammatory arthritis (IA) die prematurely from cardiovascular disease (CVD). The increased CVD risk is not fully explained by traditional risk factors, but…Abstract Number: 447 • 2013 ACR/ARHP Annual Meeting
High Levels Of Memory B CELLS ARE Associated With Response To A First ANTI-TNF Drug In Patients With Rheumatoid Arthritis
Background/Purpose: Tumor necrosis factor (TNF) inhibitors (TNFi) are effective treatments for rheumatoid arthritis (RA). Some reports suggested that TNFi affect B cell homeostasis. We studied…Abstract Number: 2678 • 2013 ACR/ARHP Annual Meeting
Medically Significant Infections Are Increased In Patients With Juvenile Idiopathic Arthritis Treated With Etanercept. Results From The British Society For Paediatric and Adolescent Rheumatology Etanercept Cohort Study
Background/Purpose: The association between anti-TNF therapy and increased rate of infection are widely documented in adults with rheumatoid arthritis. Findings in children with juvenile idiopathic…Abstract Number: 1903 • 2013 ACR/ARHP Annual Meeting
PIK3CD Overexpression In The Synovial Membrane Of Rheumatoid Arthritis Patients Is Associated With Response To Anti-TNF Therapy
Background/Purpose: The mechanisms by which Rheumatoid Arthritis (RA) patients do not respond to TNF blockade are still poorly characterized. The goal of this study is…Abstract Number: 1438 • 2013 ACR/ARHP Annual Meeting
Comparative Effectiveness Of Rituximab Vs. Subsequent Anti-Tumor Necrosis Factor In Patients With Rheumatoid Arthritis With Prior Exposure To TNFi
Background/Purpose: In patients (pts) who have failed 1 or more TNF-α inhibitors (TNFi), there is little data to guide clinical decision making in terms of…Abstract Number: 431 • 2013 ACR/ARHP Annual Meeting
Prediction Of Week 52 Treatment Response Based On A Week 12 Assessment In Rheumatoid Arthritis Patients Receiving Certolizumab Pegol: Comparison Of A Patient-Reported Instrument Versus Physician-Based Disease Activity Assessment
Background/Purpose: Guidelines support early intervention in rheumatoid arthritis (RA).1,2 The aim was to prospectively test whether outcome assessment at 12 weeks (wks) using a patient-reported…Abstract Number: 2690 • 2013 ACR/ARHP Annual Meeting
Survival Of The Second Biologic After The First Tumor Necrosis Factor Alpha Inhibitor’s Failure In The Treatment Of Rheumatoid Arthritis: Prospective Observational Data From Biorx.Si Registry
Background/Purpose: Current recommendations for management of RA propose a tumor necrosis factor alpha inhibitor (TNFi) for patients failing to achieve the treatment target with synthetic…Abstract Number: 1886 • 2013 ACR/ARHP Annual Meeting
Differential Methylation Related To Response To Etanercept In Patients With Rheumatoid Arthritis
Background/Purpose: The introduction of biologic drug therapies targeting specific components of the inflammatory response represents a huge advance in the treatment of rheumatoid arthritis (RA).…Abstract Number: 1436 • 2013 ACR/ARHP Annual Meeting
Early Changes In a Multi-Biomarker Disease Activity Score After Starting Adalimumab Treatment Predict Change In MRI Inflammation At 6 Months
Background/Purpose: A multi-biomarker disease activity (MBDA) score has been validated as a measure of disease activity in rheumatoid arthritis. This study aimed to see if…Abstract Number: 342 • 2013 ACR/ARHP Annual Meeting
TNF Blockage In Psoriatic Arthritis: Long-Term Effect On Lipid Profile
Background/Purpose: Psoriatic arthritis (PsA) patients have increased cardiovascular morbidity and mortality. Altered lipid profile is an important risk factor for the development of these complications.…Abstract Number: 2691 • 2013 ACR/ARHP Annual Meeting
Results Of The Strass Trial Regarding Impact Of Progressive Spacing Of Tnf-Blocker Injections In Rheumatoid Arthritis Patients In Das28 Remission: Is There a Difference Between Drugs – Adalimumab and Etanercept – Or Their Mode Of Use – Monotherapy Or Combination?
Background/Purpose: The STRASS trial was an 18-month randomized controlled trial, conducted in established RA patients in DAS28 remission with etanercept (ETA) or adalimumab (ADA), comparing…Abstract Number: 1862 • 2013 ACR/ARHP Annual Meeting
Target-Directed Development Of a Proposed Biosimilar Etanercept, GP2015: Comparability Of In Vitro Target Binding and Pre-Clinical Efficacy and Pharmacokinetics
Background/Purpose: Biosimilars are copy versions of existing biologic medicines that have lost patent exclusivity and are approved via stringent regulatory pathways. Biosimilars are designed to…
- « Previous Page
- 1
- …
- 20
- 21
- 22
- 23
- 24
- …
- 29
- Next Page »